#Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice

We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is …

Continue reading #Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice

Two Phase 3 Trials of Inclisiran in Patients with Elevated #LDL Cholesterol

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODSWe enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated …

Continue reading Two Phase 3 Trials of Inclisiran in Patients with Elevated #LDL Cholesterol